Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | PANK1 | Q8TE04 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053542 | 0.94 | KMT2A (0.40) | KMT2AMEN1MAPTALDH1A1RIPK1 | |
| SCHEMBL3706319 | 0.92 | RIPK1 (0.41) | KMT2AMEN1MAPTALDH1A1RIPK1 | |
| SCHEMBL15053823 | 0.92 | BRAF (0.46) | SMN1; SMN2BRAFMTNR1A | |
| SCHEMBL15053056 | 0.91 | MAPT (0.41) | KMT2AMEN1MAPTSMN1; SMN2BRAF | |
| SCHEMBL15053233 | 0.90 | KMT2A (0.42) | KMT2AMEN1ALDH1A1SMN1; SMN2KDR | |
| SCHEMBL15053062 | 0.90 | STING1 (0.45) | KDRPDGFRBTRPV1DRD2DRD4 | |
| SCHEMBL15052932 | 0.90 | KMT2A (0.41) | KMT2AMEN1MAPTRIPK1BRAF | |
| SCHEMBL15053593 | 0.90 | FGFR1 (0.44) | KMT2AMEN1MAPTALDH1A1RIPK1 | |
| SCHEMBL15053384 | 0.89 | BRAF (0.41) | MAPTSMN1; SMN2PKMKDRPDGFRB | |
| SCHEMBL15052619 | 0.89 | BRAF (0.40) | KMT2ASMN1; SMN2PKMKDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | KMT2A 834/4885MEN1 3044/4885MAPT 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.